EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose

Guillermina Ferro-Flores iD, Erika Azorín-Vega iD, Blanca Ocampo-García iD, Myrna Luna-Gutiérrez iD, Pedro Cruz-Nova iD, Laura Meléndez-Alafort iD

International Journal of Molecular Sciences · 20.07.2025 · 26 (14) · 6968

DOI: 10.3390/ijms26146968 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.07.2025. Verfasst von Guillermina Ferro-Flores und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico. Hauptthemen laut MEDLINE: Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Mexiquense de Ciencia y Tecnología" (COMECyT), International Atomic Energy Agency, Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted radionuclide therapy (TRT) utilizes radiopharmaceuticals to deliver radiation directly to cancer cells while sparing healthy tissues. Beyond the absorbed dose of ablative radiation, TRT induces non-targeted effects (NTEs) that significantly enhance its therapeutic efficacy. These effects include radiation-induced bystander effects (RIBEs), abscopal effects (AEs), radiation-induced genomic instability (RIGI), and adaptive responses, which collectively influence the behavior of cancer cells and the tumor microenvironment (TME). TRT also modulates immune responses, promoting immune-mediated cell death and enhancing the efficacy of combination therapies, such as the use of immune checkpoint inhibitors. The molecular mechanisms underlying TRT involve DNA damage, oxidative stress, and apoptosis, with repair pathways like homologous recombination (HR) and non-homologous end joining (NHEJ) playing critical roles. However, challenges such as tumor heterogeneity, hypoxia, and radioresistance limit the effectiveness of this approach. Advances in theranostics, which integrate diagnostic imaging with TRT, have enabled personalized treatment approaches, while artificial intelligence and improved dosimetry offer potential for treatment optimization. Despite the significant survival benefits of TRT in prostate cancer and neuroendocrine tumors, 30–40% of patients remain unresponsive, which highlights the need for further research into molecular pathways, long-term effects, and combined therapies. This review outlines the dual mechanisms of TRT, direct toxicity and NTEs, and discusses strategies to enhance its efficacy and expand its use in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsRadiopharmaceuticalsHumansTumor MicroenvironmentAnimalsBystander Effect

Stichwörter der Autor:innen

immunotherapytargeted radionuclide therapytherapeutic radiopharmaceuticalstumor microenvironment

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
  • Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.

ORCID-Profile: Guillermina Ferro-Flores, Erika Azorín-Vega, Blanca Ocampo-García, Myrna Luna-Gutiérrez, Pedro Cruz-Nova, Laura Meléndez-Alafort

Förderung

  • Consejo Mexiquense de Ciencia y Tecnología" (COMECyT)
  • International Atomic Energy Agency
  • Italian Ministry of Health
  • “Consejo Mexiquense de Ciencia y Tecnología” (COMECyT)
  • “BRIDGE” project “DECURTA”

Zitieren

APA

Ferro-Flores, G., Azorín-Vega, E., Ocampo-García, B., Luna-Gutiérrez, M., Cruz-Nova, P., & Meléndez-Alafort, L. (2025). Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose. International Journal of Molecular Sciences, 26(14), 6968. https://doi.org/10.3390/ijms26146968

Vancouver

Ferro-Flores G, Azorín-Vega E, Ocampo-García B, Luna-Gutiérrez M, Cruz-Nova P, Meléndez-Alafort L. Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose. International Journal of Molecular Sciences. 2025;26(14):6968. doi:10.3390/ijms26146968

BibTeX
@article{FerroFlores2025,
  author = {Ferro-Flores, Guillermina and Azorín-Vega, Erika and Ocampo-García, Blanca and Luna-Gutiérrez, Myrna and Cruz-Nova, Pedro and Meléndez-Alafort, Laura},
  title = {Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {14},
  pages = {6968},
  doi = {10.3390/ijms26146968}
}
Kostenlos starten →